<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-142042" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rh Blood Group System</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rosenkrans</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>University of North Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Doyal</surname>
            <given-names>Alexander</given-names>
          </name>
          <aff>University of North Carolina at Chapel Hill</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Rosenkrans declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexander Doyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-142042.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The Rh blood group system has been extensively studied and remains clinically relevant. This highly polymorphic system comprises over 50 expressed antigens embedded in the red blood cell (RBC) membrane. The function of these highly immunogenic proteins is&#x000a0;unknown. Patients with specific Rh phenotypes require special attention during transfusion and pregnancy to avoid potentially life-threatening complications. This activity reviews the evaluation and management of patients with&#x000a0;various Rh blood group phenotypes and highlights the role of the interprofessional healthcare team in&#x000a0;caring for these patients in various clinical settings.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Correlate specific Rh complex genotypes with clinically relevant Rh phenotypes.</p></list-item><list-item><p>Identify patients at increased risk for alloimmunization.</p></list-item><list-item><p>Assess and manage a patient with a hemolytic transfusion reaction.</p></list-item><list-item><p>Implement interprofessional team strategies for improving care coordination and communication to ensure safe transfusion processes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142042&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142042">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-142042.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The Rh blood group system has been extensively studied and remains clinically relevant to transfusion medicine. The system has over 50 antigens; the&#x000a0;5 most significant&#x000a0;antigens are D, C, c, E, and e.<xref ref-type="bibr" rid="article-142042.r1">[1]</xref> The Rh antigens are a part of proteins&#x000a0;expressed on the surface of the red blood cell (RBC) membrane. The function of these antigens is unknown; they may play a role in membrane stability and ammonium transport. Importantly, the Rh antigens are highly immunogenic; exposure often leads to antibody formation. There are various expressions of Rh antigens with clinically significant phenotypes. The most significant phenotype is Rh negative, which has notable implications during pregnancy and for patients receiving blood transfusions.<xref ref-type="bibr" rid="article-142042.r2">[2]</xref></p>
        <p>Rh blood group system International Society of Blood Transfusion (ISBT) symbol: Rh</p>
        <p>ISBT Number: 004</p>
      </sec>
      <sec id="article-142042.s3" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>The first report of the Rh blood group was in 1939 when Levine and Stetson described a pregnant woman that developed postpartum hemorrhage requiring transfusion from her husband. Even though she and her husband were ABO compatible, she developed pain and discolored urine after the transfusion. Agglutination occurred when her blood was remixed with her husband's blood. Levine and Stetson tested&#x000a0;her blood with multiple ABO-matched donors and noted agglutination with 80% of the donor samples. The authors concluded that the patient had been isoimmunized with an unknown antigen from her fetus resulting in the incompatible blood transfusion.<xref ref-type="bibr" rid="article-142042.r3">[3]</xref>&#x000a0;</p>
        <p>Landsteiner and Wiener would describe the offending antigen as Rhesus (Rh) factor because of the agglutination in their experiments using rhesus monkey blood, assuming rhesus RBCs expressed the same antigens as humans. Their work would also describe the autosomal dominant inheritance pattern of the Rh factor.<xref ref-type="bibr" rid="article-142042.r4">[4]</xref>&#x000a0;Later, it was discovered that humans and <italic toggle="yes">rhesus</italic> monkeys do not share the same RBC antigens, though the name persists. The anti-Rh antibody produced from the Rh factor would subsequently be renamed anti-D.<xref ref-type="bibr" rid="article-142042.r5">[5]</xref></p>
      </sec>
      <sec id="article-142042.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The Rh blood group system comprises 56 antigens; the five most clinically significant antigens&#x000a0;are D, C, c, E, and e. The Rh blood group is encoded by two tightly linked loci on chromosome 1p34-36. The&#x000a0;<italic toggle="yes">RHD&#x000a0;</italic>gene&#x000a0;encodes the RhD antigen, and the&#x000a0;<italic toggle="yes">RHCE</italic>&#x000a0;gene encodes RhCE antigens. <italic toggle="yes">SMP1</italic>, a sequence of unknown significance, separates<italic toggle="yes"> RHD </italic>and<italic toggle="yes"> RHCE</italic>.<xref ref-type="bibr" rid="article-142042.r6">[6]</xref>
<italic toggle="yes">RHD</italic>&#x000a0;and&#x000a0;<italic toggle="yes">RHCE&#x000a0;</italic>encode eight haplotypes of the Rh antigens in various combinations. The Rh proteins are hydrophobic transmembrane proteins embedded in the RBC phospholipid bilayer with an extracellular expression of the antigens. Interestingly, the RhD and RhCE proteins are very similar, with the first 41 amino acids identical.<xref ref-type="bibr" rid="article-142042.r7">[7]</xref>&#x000a0;</p>
        <p>Rh proteins require the presence of Rh-associated glycoprotein (RhAG) for proper assembly in the RBC membrane.<xref ref-type="bibr" rid="article-142042.r8">[8]</xref>&#x000a0;Though RhAG and the Rh proteins are similar in structure, the gene locus for RhAG is located on chromosome 6p12-21. The combination of the Rh proteins and RhAG is termed the Rh family. Various other accessory glycoproteins comprise the Rh structure, including LW glycoprotein, integrin-associated protein, glycophorin B, and band 3 glycoprotein, encoded on chromosomes 19, 3, 4, and 17, respectively. The Rh proteins, RhAG, and accessory proteins are collectively termed the Rh complex.<xref ref-type="bibr" rid="article-142042.r1">[1]</xref>&#x000a0;The function of the Rh complex is unclear. Studies of different Rh phenotypes indicate that the Rh complex plays a role in the RBC membrane integrity and may be involved with ammonium transport across the RBC membrane.<xref ref-type="bibr" rid="article-142042.r6">[6]</xref></p>
        <p>Various Rh complex phenotypes exist due to point and nonsense mutations, rearrangements, and nucleotide deletions. Of these phenotypes, a lack of D antigen (D-negative), weak D, partial D, RhCE variants, and Rh<sub>null</sub> have clinical implications.</p>
        <p>
<bold>Lack of D Antigen</bold>
</p>
        <p>The lack of D antigen (D-negative) occurs for various reasons closely linked to ethnicity. Commonly identified in White populations, the deletion of <italic toggle="yes">RHD</italic>&#x000a0;or mutations resulting in a premature stop codon produces the D-negative phenotype. In other people, the lack of D-antigen may be due to mutations preventing gene expression.&#x000a0;For example, in African populations, the presence of a pseudogene leads to base pair duplication preventing gene expression.<xref ref-type="bibr" rid="article-142042.r6">[6]</xref>&#x000a0;Patients&#x000a0;lacking D-antigen warrant special consideration to prevent alloimmunization; if exposed to D-antigen through transfusion or pregnancy, they may develop anti-D antibodies, as seen when a D-negative parturient has a D-positive fetus.<xref ref-type="bibr" rid="article-142042.r9">[9]</xref></p>
        <p>
<bold>Weak D</bold>
</p>
        <p>Approximately 1% of D-positive individuals type as weak D (historically known as Du), characterized by weak or absent RBC agglutination by anti-D antibodies during routine serologic testing.&#x000a0;In weak D individuals, the D antigen usually requires enhancement with anti-human globulin (AHG) owing to a quantitative decrease in RhD protein.<bold>&#x000a0;</bold>The weak D phenotype is a quantitative change in the D-antigen epitope caused by a defect in transcribing the <italic toggle="yes">RHD</italic> gene.<xref ref-type="bibr" rid="article-142042.r1">[1]</xref> Various weak D genotypes exist; Types 1, 2, and 3 are the most common and produce sufficient D antigen epitopes to be managed as D-positive.<xref ref-type="bibr" rid="article-142042.r10">[10]</xref>&#x000a0;Female patients of childbearing age who&#x000a0;are positive for a weak D phenotype should undergo additional genotyping to determine if immunoprophylaxis during pregnancy is necessary.<xref ref-type="bibr" rid="article-142042.r11">[11]</xref></p>
        <p>
<bold>Partial D</bold>
</p>
        <p>The partial D phenotype is a qualitative change to the D antigen epitope caused by <italic toggle="yes">RHD</italic> gene conversions, point mutations, or expression of a low-incidence antigen.<xref ref-type="bibr" rid="article-142042.r6">[6]</xref>&#x000a0;The majority of patients with partial D phenotype will type D-positive. Notably, these patients may form anti-D antibodies if exposed to D-positive RBCs&#x000a0;and&#x000a0;require special consideration for transfusion and during pregnancy.<xref ref-type="bibr" rid="article-142042.r10">[10]</xref></p>
        <p><bold>RhCE Variants&#x000a0;</bold>&#x000a0;</p>
        <p>RhCE polymorphisms occur due to single or multiple nucleotide substitutions in <italic toggle="yes">RHCE</italic>. The E and e alleles differ only by a proline to alanine substitution. However, the C and c polymorphic alleles have four different amino acid substitutions.<xref ref-type="bibr" rid="article-142042.r12">[12]</xref>&#x000a0;The expression of these different alleles significantly impacts patients receiving chronic transfusions as they may develop alloantibodies more frequently. Notably, patients with sickle cell disease are at particular risk for alloimmunization.<xref ref-type="bibr" rid="article-142042.r13">[13]</xref></p>
        <p><bold>Rh<sub>null</sub>&#x000a0;</bold>&#x000a0;</p>
        <p>Rh<sub>null</sub> phenotype contains two classifications, amorph and regulator. Amorph Rh<sub>null</sub> occurs from a mutation of&#x000a0;<italic toggle="yes">RHCE,</italic>&#x000a0;leading to nonfunctional proteins on a D-negative background. Regulator Rh-null is the most common phenotype due to an <italic toggle="yes">RHAG</italic>&#x000a0;mutation that produces&#x000a0;dysfunctional RhAG.<xref ref-type="bibr" rid="article-142042.r6">[6]</xref>&#x000a0;Clinically, Rh<sub>null</sub>&#x000a0;patients have shortened RBC life spans, characteristic RBC morphology on a peripheral blood smear and compensated hemolytic anemias. Transfusion support can be challenging because Rh<sub>null</sub> individuals can become sensitized to multiple Rh antigens, including high-frequency antigens. Some alloimmunized Rh<sub>null&#x000a0;</sub>patients can develop anti-RH29 antibodies; however, this antibody does not react with Rh<sub>null</sub> RBCs.<xref ref-type="bibr" rid="article-142042.r14">[14]</xref></p>
      </sec>
      <sec id="article-142042.s5" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>The blood sample collected in EDTA is called whole blood and is used for ABO and Rh typing.&#x000a0;EDTA is the preferred anticoagulant for hematological testing because it allows the best preservation of cellular components and morphology of blood cells.<xref ref-type="bibr" rid="article-142042.r15">[15]</xref> The minimum volume of blood required for Rh typing ranges from 0.5 to 4 mL of whole blood, depending on the laboratory and the age of the&#x000a0;patient.</p>
      </sec>
      <sec id="article-142042.s6" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>The direct antiglobulin test (DAT) demonstrates the in vivo coating of RBC surfaces with immunoglobulin antibodies or complement protein C3. The DAT is most commonly utilized for the serologic investigation of potential antibody-mediated hemolysis.<xref ref-type="bibr" rid="article-142042.r16">[16]</xref> Clinical situations warranting a DAT include acute or delayed hemolytic transfusion reactions due to antibody incompatibility, hemolytic disease of the fetus and newborn, and antibody-mediated drug-induced hemolysis. While a DAT is not routinely performed for otherwise uncomplicated pretransfusion testing, it may be informative in cases where the auto-control is reactive to confirm the presence of self-reactive antibodies.<xref ref-type="bibr" rid="article-142042.r17">[17]</xref>&#x000a0;</p>
        <p>The DAT is performed by directly adding antihuman globulin (AHG) reagent to a sample of the patient&#x02019;s RBCs and observing for agglutination with a positive reaction occurring if the RBCs are already coated such that AHG can bind. All positive DAT&#x000a0;samples should be tested with an inert control such as saline or 6% albumin before concluding a DAT test is positive.<xref ref-type="bibr" rid="article-142042.r16">[16]</xref> Various preparations of AHG sera are available for blood bank testing; the choice of AHG preparation is dictated by the application, direct or indirect, and whether testing is being performed to detect RBC sensitization by IgG, complement, or both.<xref ref-type="bibr" rid="article-142042.r18">[18]</xref></p>
        <p>The&#x000a0;indirect antiglobulin test (IAT) is performed to detect in vitro antibody binding to RBCs, regardless of the antibody&#x02019;s ability to fix complement. Laboratory indications include antibody detection as in crossmatch and antibody screening, antibody identification, antibody titration, and RBC phenotyping.&#x000a0;Antiglobulin testing may be performed using test tubes, capillary tubes, microtiter plates, or gel microtube techniques.<xref ref-type="bibr" rid="article-142042.r19">[19]</xref> To standardize antiglobulin sera and confirm true-negative antiglobulin reactions, two types of quality control RBCs are customarily used, those coated with IgG and those coated with C3b, C3d, or both. Rh antibodies are usually used to sensitize RBCs&#x000a0;with IgG.<xref ref-type="bibr" rid="article-142042.r17">[17]</xref></p>
        <p>Quality control cells for the antiglobulin test are called check cells or Coombs control cells. In a true-negative test, free active antiglobulin reagent should remain. Control cells, sensitized with IgG or C3, are added to all negative tests and centrifuged. Hemagglutination of check cells confirms the presence and reactivity of the AHG reagent, thus validating a negative test result. If the control cells fail to agglutinate in any tube, the tests must be repeated because they are invalid and may have yielded false-negative results.<xref ref-type="bibr" rid="article-142042.r20">[20]</xref></p>
        <p>Although the antiglobulin test is extremely sensitive, a negative test does not exclude the possible presence of antibodies on RBCs.&#x000a0;A negative reaction can occur with small quantities of bound IgG and C3.<xref ref-type="bibr" rid="article-142042.r16">[16]</xref> In addition, AHG sera may possess greater activity against some subclasses of IgG than others. Consequently, certain AHG sera may produce negative results with RBCs coated by a particular IgG subclass.<xref ref-type="bibr" rid="article-142042.r21">[21]</xref></p>
      </sec>
      <sec id="article-142042.s7" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Rh typing detects the presence or absence of the D antigen on the surface of RBCs and is performed analogously to ABO forward typing. During Rh typing, the RBCs of the patient are combined with reagent anti-D antibodies, and the resulting presence or absence of agglutination confers the Rh &#x0201c;positive&#x0201d; or &#x0201c;negative&#x0201d; status, respectively.<xref ref-type="bibr" rid="article-142042.r22">[22]</xref> While not routinely required for pretransfusion testing, serologic testing to detect weak D or partial D phenotypes should occur in cases of ambiguous Rh typing or discrepancies with a patient&#x02019;s historical typing result.<xref ref-type="bibr" rid="article-142042.r23">[23]</xref> In cases of an apparently negative Rh type, the serologic assessment for weak or partial D requires adding AHG reagent to enhance otherwise undetectable agglutination. Agglutination in this context suggests the presence of a weak or partial D phenotype; definitive distinction requires subsequent molecular genotyping to predict the true D antigen phenotype.<xref ref-type="bibr" rid="article-142042.r24">[24]</xref></p>
        <p>Various methods for Rh blood group testing may be employed. Serological testing is most commonly based on hemagglutination reactions with RBC antigens against specific antibodies.<xref ref-type="bibr" rid="article-142042.r25">[25]</xref>&#x000a0;The hemagglutination process occurs in&#x000a0;2 stages.&#x000a0;The first stage, often called RBC sensitization, combines paratope and epitope in a reversible reaction that follows the law of mass action and has an associated equilibrium constant. Noncovalent attractions hold together the antigen and antibody. During the second stage, multiple RBCs with bound antibodies form a stable latticework through antigen-antibody bridges formed between adjacent cells. This latticework is the basis of all visible agglutination reactions.<xref ref-type="bibr" rid="article-142042.r26">[26]</xref></p>
        <p>Reagents that detect the D antigen in the slide, tube, microplate, automated, and gel tests often have different formulations and performance characteristics. Various anti-D reagents may contain different antibody clones, potentiators, additives, or diluents, and reagents that contain the same antibody clone may vary in antibody dilution or preservative. Hence, instructions for testing may differ and must be consulted and followed carefully for accurate testing.<xref ref-type="bibr" rid="article-142042.r27">[27]</xref></p>
        <p>
<bold>Slide Testing</bold>
</p>
        <p>A glass slide containing a drop of 40% to 50% serum or plasma suspension of RBCs and a drop of anti-D is mixed and placed on a heated Rh viewing box tilted continuously for 2 minutes to observe for agglutination. To rapidly warm the materials on the slide at 37&#x000b0;C, the Rh viewing box is kept at a temperature between 40&#x000b0;C and 50&#x000b0;C. The result is positive when the patient sample shows agglutination and the control shows suspension.<xref ref-type="bibr" rid="article-142042.r28">[28]</xref> The sensitivity of this method is low and can be easily affected by multiple factors, thus making standardization difficult.<xref ref-type="bibr" rid="article-142042.r29">[29]</xref></p>
        <p>
<bold>Tube Testing</bold>
</p>
        <p>The test tube method can be utilized for emergency and first-time blood group typing. The test tube method is quicker, more sensitive, and uses fewer reagants than the slide method.<xref ref-type="bibr" rid="article-142042.r28">[28]</xref>&#x000a0;In the test tube method,&#x000a0;a patient&#x02019;s antibody-containing plasma and reagent RBCs known to express specific antigens are combined in a test tube. Alternatively, a patient&#x02019;s RBCs may be combined with reagent antibodies of known specificity. The mixture undergoes a series of centrifugation and incubation steps with stepwise quantitation of agglutination. The strongest agglutination, a 4+ reaction, results in an effectively nondissociable single clump of RBCs when the tube is gently agitated, whereas the weakest agglutination, a negative reaction, results in complete dissociation into individual RBCs by the same assessment. The intermediate strength reactions fall in a spectrum in between these extremes.<xref ref-type="bibr" rid="article-142042.r30">[30]</xref></p>
        <p>
<bold>Gel Testing</bold>
</p>
        <p>The gel testing method is a widely available alternative serologic testing method that utilizes dextran acrylamide gel-containing microtube columns built into small plastic cards.<xref ref-type="bibr" rid="article-142042.r31">[31]</xref> Antibodies containing plasma and reagent RBCs are combined in a&#x000a0;chamber above the columns, and the card is subsequently&#x000a0;centrifuged to force the RBCs down through the permeable gel, which acts like a size-selective sieve.&#x000a0;The gel is typically impregnated with AHG to facilitate agglutination. Depending on the degree of agglutination, the RBCs have varying mobility as they travel down the column, and their visible stopping point quantifies the reaction. Gel method testing can be automated and has the advantage of a more objective scale for quantifying results than tube testing.<xref ref-type="bibr" rid="article-142042.r25">[25]</xref></p>
        <p>
<bold>Microplate Agglutination Testing</bold>
</p>
        <p>The microplate technology uses automated platforms to detect serum antibodies and RBC surface antigens.<xref ref-type="bibr" rid="article-142042.r26">[26]</xref> The reactants are centrifuged and incubated in microplates, and the ABO/RH(D) blood type is read through an automated system. The antiserum must indicate that it is formulated for automation or microplate Rh testing and may require the blood to be collected in a specific anticoagulant.<xref ref-type="bibr" rid="article-142042.r25">[25]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-142042.s8" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>False positive or negative results can be caused by improper technique, contaminated materials, omission of reagents or antisera, delays in reading tests, inadequate incubation time and temperature, inappropriate centrifugation, inappropriate or prolonged storage of red cells, and autoantibodies.<xref ref-type="bibr" rid="article-142042.r32">[32]</xref></p>
      </sec>
      <sec id="article-142042.s9" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>A patient or donor RBC sample previously found to be positive but now determined to be negative, or vice versa, should always be investigated to rule out identification, clerical, or recording errors.<xref ref-type="bibr" rid="article-142042.r32">[32]</xref> A new sample should be obtained and tested. If the discrepancy is between current and historical test results, the difference may be due to the testing method employed, phase of testing (DAT or IAT), type of reagent (polyclonal vs. monoclonal), or manufacturer.<xref ref-type="bibr" rid="article-142042.r33">[33]</xref> Different reagents often contain different antibody clones that may&#x000a0;demonstrate varying reactions with RBCs with weak or partial Rh antigens. Knowledge of the ethnicity of the donor or patient can be helpful when investigating a typing discrepancy because some partial and weak phenotypes are more common in a specific ethnic group. Typing with several reagents from different manufacturers may be helpful.<xref ref-type="bibr" rid="article-142042.r34">[34]</xref></p>
      </sec>
      <sec id="article-142042.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Hemolytic Disease of the Newborn</bold>
</p>
        <p>Hemolytic disease of the newborn (HDN), or erythroblastosis fetalis, is a clinically important and potentially life-threatening condition where antibodies from an Rh-negative gravida attack an Rh-positive fetus.<xref ref-type="bibr" rid="article-142042.r35">[35]</xref>&#x000a0;Despite being described by a French midwife in 1609, HDN was not understood until the 1950s.<xref ref-type="bibr" rid="article-142042.r36">[36]</xref>&#x000a0;Before the onset of immunoprophylactic therapies, 1% of all pregnancies resulted in fetal death from HDN. HDN is currently estimated to affect 3 to 8 of every 100,000 pregnancies.&#x000a0;</p>
        <p>HDN results from maternal antibodies attacking fetal red blood cells. Typically, it is the second Rh-positive fetus that is affected. The first fetus inherits the paternal D antigen&#x000a0;following an autosomal dominant pattern, and maternal and fetal blood mixing occurs during the pregnancy. This mixing most commonly happens during labor and delivery but can theoretically occur at any time during the pregnancy. Once mixing occurs, the gravida begins producing anti-D antibodies. This constitutes alloimmunization, as the gravida is D-negative.</p>
        <p>The initial antibodies produced are IgM, which cannot cross the placental barrier. However, when isotype switching occurs, IgG antibodies are produced. The general absence of maternal&#x000a0;and fetal blood mixing during the first pregnancy and the delay of IgG antibody production make it unlikely that the first D-negative pregnancy is affected. However, in the subsequent D-negative pregnancy, IgG antibodies cross the placenta and attack the D antigens on fetal RBCs. This leads&#x000a0;to hemolysis that may result in jaundice, anemia, kernicterus, and hydrops fetalis. Intrauterine death may occur without intrauterine blood transfusion, and any surviving fetus may have developmental delays, hearing loss, and hypotonia.<xref ref-type="bibr" rid="article-142042.r35">[35]</xref></p>
        <p>
<bold>Hemolytic Transfusion Reactions</bold>
</p>
        <p>One of the more serious complications of autologous blood transfusion is a hemolytic transfusion reaction (HTR). HTR is rare, with an incidence of 1:70,000 per unit transfused.<xref ref-type="bibr" rid="article-142042.r37">[37]</xref><xref ref-type="bibr" rid="article-142042.r38">[38]</xref></p>
        <p>HTRs are caused when there is an immunological mismatch between the&#x000a0;RBCs from the blood donor and the transfusion recipient, resulting in extravascular or intravascular immune-mediated hemolysis.<xref ref-type="bibr" rid="article-142042.r37">[37]</xref>&#x000a0;An intravascular HTR is typically more clinically severe than extravascular hemolysis.<xref ref-type="bibr" rid="article-142042.r39">[39]</xref></p>
        <p>HTRs are classified by their severity and onset time, early or late.&#x000a0;HTRs greatly vary in severity from mild, clinically insignificant hemolysis presenting weeks after the transfusion to very sudden and life-threatening intravascular hemolysis leading to shock, renal failure, disseminated intravascular coagulation, and death. The main determining factor of the reaction's onset and severity is the antibody's class, such as IgG, IgM, IgG subclass, or complement binding, the antigens targeted, and their titer concentration.<xref ref-type="bibr" rid="article-142042.r40">[40]</xref></p>
        <p>The most severe type of HTR occurs during an ABO mismatch, typically due to clerical error. Patients who create AB antigens do so because of molecular mimicry to antigen presentation of gastrointestinal bacteria. These antibodies are typically IgM but may also be IgG. Severe reactions occur when IgM binds to ABO-typed&#x000a0;antigens on RBCs and subsequently fixes complement, creating a sudden, massive intravascular rupture of RBCs. Hemolysis releases large amounts of hemoglobin, resulting in shock, renal failure, and DIC leading to hemorrhage and hypercoagulability&#x000a0;with thrombosis.</p>
        <p>Extravascular HTRs occur when the antibody targeting the RBCs results in opsonization. Opsonized cells are sequestered by the macrophages of the reticuloendothelial system, primarily in the liver and spleen. Extravascular hemolysis is a comparatively slower and more progressive process, as each RBC may make several passes through the reticuloendothelial system before being phagocytosed. Unlike intravascular hemolysis, the hemoglobin is released inside the sequestering macrophage, where it is processed normally. The clinical manifestations of extravascular hemolysis are typically milder, resulting in hyperbilirubinemia and fever. However, more severe complications, such as kidney failure, may also occur.<xref ref-type="bibr" rid="article-142042.r39">[39]</xref></p>
        <p>
<bold>Immune-mediated Hemolytic Anemia</bold>
</p>
        <p>Immune-mediated hemolytic anemia occurs&#x000a0;when autoantibodies bind to RBCs, resulting in hemolysis and possible anemia. The autoantibodies are generally IgG, although IgM and IgA have also been reported.<xref ref-type="bibr" rid="article-142042.r41">[41]</xref>&#x000a0;Particular subclasses of antibodies are more destructive than others; IgG1 and IgG3 can fix complement at a high rate and are very destructive. The&#x000a0;RBCs are mainly cleared through the reticuloendothelial system, but intravascular hemolysis may occur in severe cases.</p>
        <p>Like many autoimmune disorders, most&#x000a0;immune-mediated hemolytic anemias are associated with an underlying or triggering condition. Common triggering conditions are viral infections, autoimmune disorders, immunodeficiency, or pregnancy. Rarer instances of medication interactions, spider bites, sickle cell disease, babesiosis, and organ transplants have been documented.<xref ref-type="bibr" rid="article-142042.r42">[42]</xref></p>
      </sec>
      <sec id="article-142042.s11" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>All blood centers, hospital blood banks, and collection centers must establish and implement a quality management system guided by requirements of established standards, guidelines, and principles. It is the responsibility of the management to ensure that each personnel has a clear job description which includes lines of authority and responsibility.<xref ref-type="bibr" rid="article-142042.r43">[43]</xref>&#x000a0;Each personnel must be adequately trained and assessed to be competent in the specified task before being allowed to carry out the task independently.&#x000a0;Records of training and assessment of competency are established and systematically maintained.<xref ref-type="bibr" rid="article-142042.r44">[44]</xref></p>
        <p>All critical equipment that impacts the quality of tests or blood components prepared must be operated within their defined specifications.&#x000a0;Materials used in laboratory tests and processing must be appropriately validated. All reagents shall be used and controlled according to the manufacturer's instructions.&#x000a0;All anti-sera must be visually inspected for contamination, such as discoloration, cloudiness, turbidity, or particulate matter.&#x000a0;The visual inspection results, reagent lot number, expiry date, inspection date, and the individual performing the inspection must be documented.&#x000a0;The expiry date should be checked on each reagent used.<xref ref-type="bibr" rid="article-142042.r45">[45]</xref> Do not use reagents beyond the expiry date.&#x000a0;The reactivity of blood grouping reagents shall be confirmed daily by control tests with known antigen-positive and&#x000a0;negative red cells.<xref ref-type="bibr" rid="article-142042.r46">[46]</xref></p>
        <p>Under CLIA regulations, all laboratories that perform non-waived testing must enroll in and perform proficiency testing (PT) using one of the CMS-approved PT providers.&#x000a0;The PT programs are required to provide a minimum of&#x000a0;5 samples per testing event, with&#x000a0;3 testing events per year. The minimum&#x000a0;acceptable score for satisfactory participation in immunohematology PT is&#x000a0;100% for each analyte and overall testing event score for the ABO group and Rh(D) typing.<xref ref-type="bibr" rid="article-142042.r47">[47]</xref></p>
        <p>The blood centers, hospital blood banks, and collection centers must establish policies and procedures on safety and security. Relevant committees should maintain and continually improve safety and security in the organization.<xref ref-type="bibr" rid="article-142042.r48">[48]</xref>&#x000a0;Access to the laboratory area must be restricted to authorized personnel only.&#x000a0;Staff must wear white coats on entering the laboratory and remove them before leaving the laboratory. Keep the laboratory clean and tidy and retain only necessary items. Do not store food or personal items in the laboratory, especially in the main area of the laboratory. Wash hands with soap and water before leaving the laboratory. Eating, drinking, smoking, and applying cosmetics are strictly prohibited in the laboratory. Prevent the formation of aerosols or splashing of materials. Consider all specimens as potentially infectious. Any spillage, waste, or reusable materials must be appropriately decontaminated by bleach solution before disposal. Dispose of all needles and lancets into secured, puncture-proof containers located as close as possible to where they are to be used, and then handle them as infected materials.<xref ref-type="bibr" rid="article-142042.r45">[45]</xref></p>
      </sec>
      <sec id="article-142042.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with known Rh antibodies require additional testing to receive transfusions safely. This includes knowledge of transfusion reactions, compatibility testing, and, in some cases, genotyping. Healthcare practitioners should be attuned to the possibility of patients developing new and rare antibodies, especially&#x000a0;those undergoing chronic transfusion. There should be established protocols and guidelines to ensure safe transfusion practices for patients with different Rh blood group phenotypes. This may involve additional consultation with a hematologist. Clinicians must ensure that transfusions are necessary as each transfusion may lead to the alloimmunization of Rh antigens.</p>
        <p>Communication is essential for ensuring safe transfusion practices. Healthcare team members must confirm that the correct blood product is administered to the correct patient at the correct time. Likewise, all healthcare team members should know the patient's transfusion history, allergies, and other relevant medical information.</p>
      </sec>
      <sec id="article-142042.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142042&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142042">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/142042/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=142042">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-142042.s14">
        <title>References</title>
        <ref id="article-142042.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avent</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>The Rh blood group system: a review.</article-title>
            <source>Blood</source>
            <year>2000</year>
            <month>Jan</month>
            <day>15</day>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>375</fpage>
            <page-range>375-87</page-range>
            <pub-id pub-id-type="pmid">10627438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cartron</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Defining the Rh blood group antigens. Biochemistry and molecular genetics.</article-title>
            <source>Blood Rev</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>199</fpage>
            <page-range>199-212</page-range>
            <pub-id pub-id-type="pmid">7888828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stetson</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Landmark article July 8, 1939. An unusual case of intra-group agglutination. By Philip Levine and Rufus E Stetson.</article-title>
            <source>JAMA</source>
            <year>1984</year>
            <month>Mar</month>
            <day>09</day>
            <volume>251</volume>
            <issue>10</issue>
            <fpage>1316</fpage>
            <page-range>1316-7</page-range>
            <pub-id pub-id-type="pmid">6366259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landsteiner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wiener</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>STUDIES ON AN AGGLUTINOGEN (Rh) IN HUMAN BLOOD REACTING WITH ANTI-RHESUS SERA AND WITH HUMAN ISOANTIBODIES.</article-title>
            <source>J Exp Med</source>
            <year>1941</year>
            <month>Sep</month>
            <day>30</day>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-20</page-range>
            <pub-id pub-id-type="pmid">19871137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LEVINE</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>CELANO</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>WALLACE</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>SANGER</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A human "D-like" antibody.</article-title>
            <source>Nature</source>
            <year>1963</year>
            <month>May</month>
            <day>11</day>
            <volume>198</volume>
            <fpage>596</fpage>
            <page-range>596-7</page-range>
            <pub-id pub-id-type="pmid">13930159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Kim</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cartron</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Rh proteins: key structural and functional components of the red cell membrane.</article-title>
            <source>Blood Rev</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-110</page-range>
            <pub-id pub-id-type="pmid">15961204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avent</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Ridgwell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanner</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Anstee</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>cDNA cloning of a 30 kDa erythrocyte membrane protein associated with Rh (Rhesus)-blood-group-antigen expression.</article-title>
            <source>Biochem J</source>
            <year>1990</year>
            <month>Nov</month>
            <day>01</day>
            <volume>271</volume>
            <issue>3</issue>
            <fpage>821</fpage>
            <page-range>821-5</page-range>
            <pub-id pub-id-type="pmid">2123099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westhoff</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>The Rh blood group system in review: a new face for the next decade.</article-title>
            <source>Transfusion</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>1663</fpage>
            <page-range>1663-73</page-range>
            <pub-id pub-id-type="pmid">15504174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tormey</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hendrickson</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-related red blood cell alloantibodies: induction and consequences.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Apr</month>
            <day>25</day>
            <volume>133</volume>
            <issue>17</issue>
            <fpage>1821</fpage>
            <page-range>1821-1830</page-range>
            <pub-id pub-id-type="pmid">30808636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandler</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Queenan</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>A Guide to Terminology for Rh Immunoprophylaxis.</article-title>
            <source>Obstet Gynecol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>633</fpage>
            <page-range>633-635</page-range>
            <pub-id pub-id-type="pmid">28796682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandler</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Flegel</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Westhoff</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Denomme</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Queenan</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>CD</given-names>
              </name>
              <collab>College of American Pathologists Transfusion Medicine Resource Committee Work Group</collab>
            </person-group>
            <article-title>It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.</article-title>
            <source>Transfusion</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>680</fpage>
            <page-range>680-9</page-range>
            <pub-id pub-id-type="pmid">25438646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ch&#x000e9;rif-Zahar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cartron</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Le Van Kim</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetic basis of the human Rhesus blood group system.</article-title>
            <source>Nat Genet</source>
            <year>1993</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-5</page-range>
            <pub-id pub-id-type="pmid">8220426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vege</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith-Whitley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Westhoff</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Aug</month>
            <day>08</day>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>1062</fpage>
            <page-range>1062-71</page-range>
            <pub-id pub-id-type="pmid">23723452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flegel</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>The genetics of the Rhesus blood group system.</article-title>
            <source>Blood Transfus</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>50</fpage>
            <page-range>50-7</page-range>
            <pub-id pub-id-type="pmid">19204754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wiseman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacLeod</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zayed</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of polyethylene terephthalate for ABO and Rh typing and alloantibody screening.</article-title>
            <source>Transfusion</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>669</fpage>
            <page-range>669-72</page-range>
            <pub-id pub-id-type="pmid">10864986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tormey</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>The Direct Antiglobulin Test: Indications, Interpretation, and Pitfalls.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>305</fpage>
            <page-range>305-310</page-range>
            <pub-id pub-id-type="pmid">28134589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zantek</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Koepsell</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tharp</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>The direct antiglobulin test: a critical step in the evaluation of hemolysis.</article-title>
            <source>Am J Hematol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>87</volume>
            <issue>7</issue>
            <fpage>707</fpage>
            <page-range>707-9</page-range>
            <pub-id pub-id-type="pmid">22566278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x00131;&#x000e7;ak&#x000e7;&#x00131;</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>&#x000d6;zt&#x000fc;rkmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akyay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olcay</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>False positive result of the direct antiglobulin test (DAT): the role of the elevated level of immunoglobulin G.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>611</fpage>
            <page-range>611-9</page-range>
            <pub-id pub-id-type="pmid">22732104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sigdel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chalise</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bolideei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malla</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Comparison between the Manual Method of Indirect Coombs via Gel Technology and Solid Phase Red Cell Adherence.</article-title>
            <source>Maedica (Bucur)</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-206</page-range>
            <pub-id pub-id-type="pmid">34621340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devignes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le Pennec</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Gien</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mannessier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rouger</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[The direct antiglobulin and elution tests: evaluation of quality control in Blood Transfusion Centers].</article-title>
            <source>Transfus Clin Biol</source>
            <year>1996</year>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-6</page-range>
            <pub-id pub-id-type="pmid">8983517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidarsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rispens</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>IgG subclasses and allotypes: from structure to effector functions.</article-title>
            <source>Front Immunol</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>520</fpage>
            <pub-id pub-id-type="pmid">25368619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Blood groups systems.</article-title>
            <source>Indian J Anaesth</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>524</fpage>
            <page-range>524-8</page-range>
            <pub-id pub-id-type="pmid">25535412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castiglia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arena</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gangi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mazzola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vasto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Weak D and partial D: our experience in daily activity.</article-title>
            <source>Blood Transfus</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-6</page-range>
            <pub-id pub-id-type="pmid">22337276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westhoff</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Review: the Rh blood group D antigen... dominant, diverse, and difficult.</article-title>
            <source>Immunohematology</source>
            <year>2005</year>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>155</fpage>
            <page-range>155-63</page-range>
            <pub-id pub-id-type="pmid">16472017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Blood Group Testing.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>827619</fpage>
            <pub-id pub-id-type="pmid">35223922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quraishy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sapatnekar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Advances in Blood Typing.</article-title>
            <source>Adv Clin Chem</source>
            <year>2016</year>
            <volume>77</volume>
            <fpage>221</fpage>
            <page-range>221-269</page-range>
            <pub-id pub-id-type="pmid">27717418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Quality control of indispensable reagent RBC for ABO typing].</article-title>
            <source>Zhongguo Shi Yan Xue Ye Xue Za Zhi</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>1289</fpage>
            <page-range>1289-92</page-range>
            <pub-id pub-id-type="pmid">18088486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mujahid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dickert</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Blood Group Typing: From Classical Strategies to the Application of Synthetic Antibodies Generated by Molecular Imprinting.</article-title>
            <source>Sensors (Basel)</source>
            <year>2015</year>
            <month>Dec</month>
            <day>31</day>
            <volume>16</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">26729127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malomgr&#x000e9;</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Neumeister</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Recent and future trends in blood group typing.</article-title>
            <source>Anal Bioanal Chem</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>393</volume>
            <issue>5</issue>
            <fpage>1443</fpage>
            <page-range>1443-51</page-range>
            <pub-id pub-id-type="pmid">18839152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makarovska-Bojadzieva</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blagoevska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolevski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kostovska</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Optimal blood grouping and antibody screening for safe transfusion.</article-title>
            <source>Prilozi</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-28</page-range>
            <pub-id pub-id-type="pmid">19736535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langston</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Procter</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cipolone</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Stroncek</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the gel system for ABO grouping and D typing.</article-title>
            <source>Transfusion</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>300</fpage>
            <page-range>300-5</page-range>
            <pub-id pub-id-type="pmid">10204594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menegati</surname>
                <given-names>SFP</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Macedo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Castilho</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Discrepancies between red cell phenotyping and genotyping in daily immunohematology laboratory practice.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>102585</fpage>
            <pub-id pub-id-type="pmid">31303508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Javadzadeh Shahshahani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hayati</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Blood Group Discrepancies at a Regional Blood Center.</article-title>
            <source>Int J Hematol Oncol Stem Cell Res</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">32337013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Blood group discrepancies at a tertiary care centre - analysis and resolution.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>481</fpage>
            <page-range>481-7</page-range>
            <pub-id pub-id-type="pmid">24325154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myle</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Al-Khattabi</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects.</article-title>
            <source>Pediatric Health Med Ther</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>491</fpage>
            <page-range>491-498</page-range>
            <pub-id pub-id-type="pmid">34675752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic Disease of the Fetus and Newborn: Historical and Current State.</article-title>
            <source>Clin Lab Med</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-151</page-range>
            <pub-id pub-id-type="pmid">33494881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strobel</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic Transfusion Reactions.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2008</year>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>346</fpage>
            <page-range>346-353</page-range>
            <pub-id pub-id-type="pmid">21512623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harewood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramsey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Master</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <chapter-title>Hemolytic Transfusion Reaction</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">28846280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panch</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Montemayor-Garcia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic Transfusion Reactions.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>11</day>
            <volume>381</volume>
            <issue>2</issue>
            <fpage>150</fpage>
            <page-range>150-162</page-range>
            <pub-id pub-id-type="pmid">31291517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brand</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immunological complications of blood transfusions.</article-title>
            <source>Presse Med</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>45</volume>
            <issue>7-8 Pt 2</issue>
            <fpage>e313</fpage>
            <page-range>e313-24</page-range>
            <pub-id pub-id-type="pmid">27499223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodsky</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Warm Autoimmune Hemolytic Anemia.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>15</day>
            <volume>381</volume>
            <issue>7</issue>
            <fpage>647</fpage>
            <page-range>647-654</page-range>
            <pub-id pub-id-type="pmid">31412178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michalak</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Olewicz-Gawlik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rupa-Matysek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolny-Rokicka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nowakowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia: current knowledge and perspectives.</article-title>
            <source>Immun Ageing</source>
            <year>2020</year>
            <month>Nov</month>
            <day>20</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">33292368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smit-Sibinga</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Total quality management in blood transfusion.</article-title>
            <source>Vox Sang</source>
            <year>2000</year>
            <volume>78 Suppl 2</volume>
            <fpage>281</fpage>
            <page-range>281-6</page-range>
            <pub-id pub-id-type="pmid">10938970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mueller</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Seifried</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.</article-title>
            <source>Transfus Clin Biol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>282</fpage>
            <page-range>282-5; quiz 286-9</page-range>
            <pub-id pub-id-type="pmid">17196864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chevrolle</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Quality assurance in blood transfusion].</article-title>
            <source>Ann Pharm Fr</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>318</fpage>
            <page-range>318-25</page-range>
            <pub-id pub-id-type="pmid">12378141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabaud</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>[Training, skill and competences' follow-up].</article-title>
            <source>Transfus Clin Biol</source>
            <year>2007</year>
            <month>May</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>152</fpage>
            <page-range>152-6</page-range>
            <pub-id pub-id-type="pmid">17524697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaudhary</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ojha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khetan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sonker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The external quality assessment scheme: Five years experience as a participating laboratory.</article-title>
            <source>Asian J Transfus Sci</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-30</page-range>
            <pub-id pub-id-type="pmid">20376263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142042.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elgemmezi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cha&#x00457;b</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bou Assi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abu Helu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hmida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benajiba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alqudah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abi Hanna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Najjar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Garraud</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Quality and safety measures in transfusion practice: The experience of eight southern/eastern Mediterranean countries.</article-title>
            <source>Vox Sang</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>405</fpage>
            <page-range>405-423</page-range>
            <pub-id pub-id-type="pmid">32124457</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
